Table 2

Correlation of PDGFR A13 and B19 mutational status and clinical-pathological features
Clinical features PDGFRα exon 13 PDGFRβ exon 19
WT N (%) SNP N (%) p WT N (%) SNP N (%) p
Gender 0.754 0.346
 · Female 24 (85.7) 4 (14.3) 10 (34.5) 19 (65.5)
 · Male 36 (80.0) 9 (20.0) 23 (46.9) 26 (53.1)
Age 0.127 0.653
 · ≤ 68-years old (median) 34 (89.5) 4 (10.5) 18 (45.0) 22 (55.0)
 · > 68-years old (median) 26 (74.3) 9 (25.7) 15 (39.5) 23 (60.5)
CEA (carcinoembryonic antigen) 1.000 0.813
 · Within normal range 39 (83.0) 8 (17.0) 21 (41.2) 30 (58.8)
 · ≥ ULN (5 ng/ml) 21 (80.8) 5 (19.2) 12 (44.4) 15 (55.6)
Primary tumour location 1.000 0.051
 · Colon 47 (82.5) 10 (17.5) 22 (36.1) 39 (63.9)
Rectum 13 (81.3) 3 (18.8) 11 (64.7) 6 (35.3)
Tumour histology 0.401 0.221
 · Conventional adenocarcinoma 52 (83.9) 10 (16.1) 30 (45.5) 36 (54.5)
 · Mucinous or colloid adenocarcinoma 8 (72.7) 3 (27.3) 3 (25.0) 9 (75.0)
TNM stage 0.196 0.170
 · I-II 23 (92.0) 2 (8.0) 8 (30.8) 18 (69.2)
 · III-IV 37 (78.7) 10 (21.3) 24 (47.1) 27 (52.9)
Tumour differentiation 0.053 0.586
 · Well differentiated 15 (100) 0 (0.0) 7 (36.8) 12 (63.3)
 · Moderately or poorly differentiated 37 (77.1) 11 (22.9) 23 (47.9) 25 (52.1)
Surgery of primary tumor 0.578 0.389
 · Yes 55 (80.9) 13 (19.1) 32 (43.8) 41 (56.2)
 · No 5 (100.0) 0 (0.0) 1 (20.0) 4 (80.0)
Surgery of metastasis 0.953 0.451
 · Yes 13 (86.7) 2 (13.3) 9 (50.0) 9 (50.0)
 · No 47 (81.0) 11 (19.0) 24 (40.0) 24 (40.0)
Adjuvant chemotherapy 0.295 0.986
 · Yes 28 (87.5) 4 (12.5) 14 (42.4) 19 (57.6)
 · No 32 (78.0) 9 (22.0) 19 (42.2) 26 (57.8)
Chemotherapy for advanced disease 0.683 0.929
 · Yes 36 (83.7) 7 (16.3) 18 (41.9) 25 (58.1)
 · No 24 (80.0) 6 (20.0) 15 (42.9) 20 (57.1)

Estevez-Garcia et al.

Estevez-Garcia et al. BMC Cancer 2012 12:514   doi:10.1186/1471-2407-12-514

Open Data